Thermo Fisher Scientific Inc.
673.82USD
-2.7200 (-0.40%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on TMO.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 44.9B | 42.9B | 42.9B | 44.6B | 48.0B | 50.5B |
| Q1 | 11.8B | 10.7B | 10.3B | 10.4B | 11.0B | 11.7B |
| Q2 | 11.0B | 10.7B | 10.5B | 10.9B | 12.0B | — |
| Q3 | 10.7B | 10.6B | 10.6B | 11.1B | 12.9B | — |
| Q4 | 11.5B* | 10.9B* | 11.4B* | 12.2B* | 12.9B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 17.63 | 15.45 | 16.53 | 17.74 | 25.26 | 27.74 |
| Q1 | 5.61 | 3.32 | 3.46 | 3.98 | 4.43 | 6.05 |
| Q2 | 4.22 | 3.51 | 4.04 | 4.28 | 4.68 | — |
| Q3 | 3.79 | 4.42 | 4.25 | 4.27 | 7.14 | — |
| Q4 | 3.99* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| 4.24* |
| 4.78* |
| 5.20* |
| 7.14 |
| — |
Debt level and coverage